Summary & Overview
HCPCS M1409: BRCA1/BRCA2 Germline Testing or Genetic Counseling within 6 Months
HCPCS Level II code M1409 denotes provision of germline testing for BRCA1 and BRCA2 or completion of genetic counseling within six months of a qualifying diagnosis. This measure captures early genetic risk assessment actions that can influence treatment planning, surveillance, and family risk communication. Nationally, timely BRCA testing and counseling are central to precision oncology and hereditary cancer risk management.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise policy and billing overview, clinical context for BRCA-focused genetic services, and guidance on typical sites of service. The publication outlines benchmarks and payer coverage trends where available, highlights documentation and timing considerations inherent to this service, and summarizes implications for care coordination and downstream services.
This summary is intended for providers, billing and compliance teams, and policy analysts seeking a clear, national-level briefing on HCPCS Level II code M1409, its clinical purpose, and the payer landscape relevant to BRCA germline testing and genetic counseling performed near the time of diagnosis.
Billing Code Overview
HCPCS Level II code M1409 identifies patients who received germline testing for BRCA1 and BRCA2 or genetic counseling completed within six months of diagnosis. This service focuses on genetic risk assessment related to hereditary breast and ovarian cancer.
Service type: Genetic testing and genetic counseling coordination
Typical site of service: Ambulatory specialty clinics, oncology practices, genetic counseling clinics, and outpatient testing centers
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related billing lines.
Clinical & Coding Specifications
Clinical Context
A 42-year-old woman is diagnosed with invasive ductal carcinoma of the breast after diagnostic biopsy. Within two weeks of diagnosis she receives a referral to clinical genetics and undergoes germline testing for BRCA1 and BRCA2, or she completes a documented genetic counseling session addressing hereditary breast and ovarian cancer risk. The clinical workflow begins with diagnosis and staging visits in an oncology clinic or breast center (outpatient clinic). The oncology team documents family history and indications for testing, obtains informed consent, and orders a germline BRCA panel through a certified laboratory. Genetic counseling is provided by a board-certified genetic counselor or medical geneticist either in-person in the outpatient clinic, via a genetics clinic visit, or by telehealth. Test results are reviewed with the patient and care plan adjustments (surgical planning, systemic therapy considerations, and family cascade testing referrals) are documented. Typical sites of service include outpatient oncology clinics, breast centers, genetics clinics, and telehealth platforms used for genetic counseling encounters.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documentation supports substantially greater effort during a counseling visit (unusual complexity) beyond typical session time. |